Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LOX | P28300 | 6/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192517 | 0.90 | EPHX2 (0.50) | EPHX2TSHRLOXLOXL2ALOX5 | |
| SCHEMBL4197131 | 0.87 | EPHX2 (0.60) | EPHX2TSHRALOX5LMNAMAPK1 | |
| SCHEMBL13876785 | 0.85 | EPHX2 (0.53) | EPHX2LOXLOXL2P2RX7 | |
| SCHEMBL4197655 | 0.83 | GRM5 (0.57) | EPHX2TSHRLMNAGRM5MAPK1 | |
| SCHEMBL13876106 | 0.83 | EPHX2 (0.53) | EPHX2TSHRLOXLOXL2LMNA | |
| SCHEMBL4178412 | 0.82 | TSHR (0.52) | EPHX2TSHRLMNAMAPK1NLRP1 | |
| SCHEMBL4197019 | 0.82 | EPHX2 (0.51) | EPHX2TSHRALOX5LMNAMAPK1 | |
| SCHEMBL4192919 | 0.81 | EPHX2 (0.52) | EPHX2TSHRLMNAMAPK1NLRP1 | |
| SCHEMBL4199501 | 0.80 | TSHR (0.64) | EPHX2TSHRLMNAMAPK1NLRP1 | |
| SCHEMBL13876172 | 0.79 | TSHR (0.59) | EPHX2TSHRALOX5LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2007098352-A2 | SUBSTITUTED PYRIDINEAMIDE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885TSHR 4438/4885LOX 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.